Literature DB >> 24532364

Over compliance with capecitabine oral chemotherapy.

Jennifer Allen1, Steve Williamson.   

Abstract

CASE: A case study of a patient who over complied with adjuvant capecitabine monotherapy on several occasions is described. The patient suffered worsening side effects, predominantly palmar plantar erythrodysesthesia which resulted in dose reduction and delay. The patient had disregarded advice to stop taking the capecitabine as he perceived it as "important to fight his cancer". The patient refused review with a psychologist.
CONCLUSION: There is a lack of evidence regarding the issue of over compliance. Pharmacists should consider discussing patient's attitudes towards taking their medication and its importance to them in treating their cancer. Tools that are used to assess non-compliance could be utilised to identify patients who over comply. Further research is required to gain further understanding of the psychological factors behind patient's decisions to over comply with treatment.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24532364     DOI: 10.1007/s11096-014-9921-1

Source DB:  PubMed          Journal:  Int J Clin Pharm


  9 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  Refill adherence to repeat prescriptions of cancer drugs to ambulatory patients.

Authors:  J L G Nilsson; K Andersson; A Bergkvist; I Björkman; A Brismar; J Moen
Journal:  Eur J Cancer Care (Engl)       Date:  2006-07       Impact factor: 2.520

3.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Authors:  David Marin; Alexandra Bazeos; Francois-Xavier Mahon; Lina Eliasson; Dragana Milojkovic; Marco Bua; Jane F Apperley; Richard Szydlo; Ritti Desai; Kasia Kozlowski; Christos Paliompeis; Victoria Latham; Letizia Foroni; Mathieu Molimard; Alistair Reid; Katy Rezvani; Hugues de Lavallade; Cristina Guallar; John Goldman; Jamshid S Khorashad
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

4.  Perceptions and experiences of patients receiving oral chemotherapy.

Authors:  Brett Simchowitz; Lawrence Shiman; Justin Spencer; Daniela Brouillard; Anne Gross; Maureen Connor; Saul N Weingart
Journal:  Clin J Oncol Nurs       Date:  2010-08       Impact factor: 1.027

5.  Adherence to oral cancer therapies: nursing interventions.

Authors:  Debra Winkeljohn
Journal:  Clin J Oncol Nurs       Date:  2010-08       Impact factor: 1.027

6.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Authors:  Ann H Partridge; Philip S Wang; Eric P Winer; Jerry Avorn
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

7.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

8.  The use of erlotinib in daily practice: a study on adherence and patients' experiences.

Authors:  Lonneke Timmers; Christel C L M Boons; Dirk Mangnus; Josee E Moes; Eleonora L Swart; Epie Boven; Egbert F Smit; Jacqueline G Hugtenburg
Journal:  BMC Cancer       Date:  2011-07-01       Impact factor: 4.430

9.  The use of capecitabine in daily practice: a study on adherence and patients' experiences.

Authors:  Lonneke Timmers; Eleonora L Swart; Christel Clm Boons; Dirk Mangnus; Peter M van de Ven; Godefridus J Peters; Epie Boven; Jacqueline G Hugtenburg
Journal:  Patient Prefer Adherence       Date:  2012-10-19       Impact factor: 2.711

  9 in total
  2 in total

1.  Development and validation of oral chemotherapy self-management scale.

Authors:  Qi Peng; Wanying Wu
Journal:  BMC Cancer       Date:  2020-09-16       Impact factor: 4.430

2.  Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center.

Authors:  Jochen Hefner; Sara Berberich; Elena Lanvers; Maria Sanning; Ann-Kathrin Steimer; Volker Kunzmann
Journal:  Patient Prefer Adherence       Date:  2018-09-21       Impact factor: 2.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.